Core Insights - Telo Genomics Corp. has relocated its clinical laboratories and offices to a new, larger facility in the Greater Toronto Area to accommodate the increasing volume of clinical and research samples [1][2] - The new laboratory is expected to enhance the company's operational capacity, accelerate research programs, and improve service to clinical partners [3] - The company also announced the resignation of Hugh Rogers from its Board of Directors, acknowledging his contributions during his tenure [3] Company Overview - Telo Genomics is a biotech company specializing in telomere analysis for diagnostic and prognostic tests, particularly in oncology and neurological diseases [4] - The company is developing liquid biopsy technologies, which are less invasive and more replicable than traditional diagnostic methods, aiming to improve patient care [4] - Telo Genomics has a strong foundation in research, with over 160 peer-reviewed publications and more than 30 clinical studies involving over 3,000 patients [4]